AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2020

Dec 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2020-12-03

Reporting Person: Biller Jonathan (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-03	Common stock	M	5753	—	Acquired	11747	Direct
2020-12-03	Common stock	F	1707	$45.87	Disposed	10040	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-03	Restricted stock units	$	M	5753	Disposed		Common stock (5753.0)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.